Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.84 |
| ▸ | HSP90AB1 | P08238 | 17/20 | 0.84 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.62 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005048 | 0.93 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL5004732 | 0.93 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL3634060 | 0.93 | HSP90AA1 (0.90) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL1220650 | 0.92 | HSP90AA1 (0.93) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL1220501 | 0.91 | HSP90AB1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL1219907 | 0.90 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL1220500 | 0.90 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL3631683 | 0.90 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL1220463 | 0.90 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 | |
| SCHEMBL1746155 | 0.89 | HSP90AB1 (0.82) | HSP90AA1HSP90AB1HSP90B1TRAP1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146967-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | Serenex, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | claimed |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-05-26 | — | — | US | disclosed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | HSF1, HSP90AB1, TPH1 | HSP90AA1 4/4885HSP90AB1 2/4885HSP90B1 13/4885 |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.